WeightControl.com Interview with:
Shauna Levy MD, MS, FACS. FASMBS, DABOM
Assistant Professor
Department of Surgery
Division of Bariatric and Minimally Invasive Surgery
Director of Bariatric Surgery
American Board of Obesity Medicine, Diplomate
Instagram @tulane_bariatric_center
Tulaneweightloss.com
WeightControl.com: What is the background for this study?
Response: The SELECT trial evaluated over 17,000 patients with a history of overweight or obesity and cardiovascular disease. They randomized patients to usual care versus Wegovy (semaglutide), which is an anti-obesity medication. It is important to note that none of the participants had diabetes.
They evaluated the incidence of Major Adverse Cardiaovascular Events (MACE) for up to 5 years for all participants.